Report by Simon Collins, HIV i-Base
Almost as soon as long-acting injectable HIV drugs were approved, independent researchers wanted to look at their use in several off-label indications where they had the potential to help people who had particular difficulties with oral ART — one of which is a combination of 2-monthly CAB-LA with 6-monthly lenacapavir as a new injectable regimen.
However, this strategy appears to be actively blocked by both ViiV Healthcare and Gilead Sciences (the manufacturers of CAB-LA and lenacapavir, respectively), perhaps to try to protect in-house pipeline combinations. These pipeline combinations, however, will take many years to develop, and this will not help people who depend on injectable ART now, especially in low-income countries where both drugs are already available as PrEP.
Read the full report here.
Source : HIV i-Base
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.